Type and hit ENTER

ProAxsis specialises in four key areas of business:

Neutrophil Elastase Airways Test
  • Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017. Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months.
Clinical research services
Academic and Pharmaceutical Company Researchers
  • Our experienced team can provide a number of services for both academic and pharmaceutical company researchers, and are able to offer sample analysis at our purpose-built laboratory for a range of proteases and other inflammatory biomarkers.
ProAxsis R&D Projects
are supported by a variety of external partners
  • ProAxsis has a number of R&D projects ongoing, whch are supported by a variety of external partners. We are also able to conduct bespoke R&D projects at the request of academic groups or pharmaceutical companies.


ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active proteases and other inflammatory biomarkers, today announces a significant change to its investor base. Netscientific, who previously held a 56.4% equity share of ProAxsis, have taken full control of the company through acquisition of all …

October 16, 2020

ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been awarded an Innovate UK grant as part of the “business-led innovation in response to global disruption” scheme, which was set up in light of the COVID-19 pandemic.  The £50,000 award will be utilised to …

August 3, 2020

Belfast based respiratory diagnostics company, ProAxsis is investing over £200,000 in R&D to enhance its novel ProteaseTag® technology. The company is using Invest Northern Ireland’s support for R&D to develop new diagnostic biomarker tests which will help to identify critical signs of clinical deterioration for patients suffering …

July 27, 2020
ProAxsis | developing products for the capture, detection and measurement of active protease biomarkers of disease